Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma

Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population‐based cohort study

“…Very few population‐based studies have previously addressed the impact of comorbidities on overall survival in MCL (Cohen et al , ; Yamasaki et al , ; Kyriakou et al , ), and none the impact on lymphoma‐specific survival, despite that nearly half of the patients have comorbidities at diagnosis. A large study of 8,029 MCL patients showed that among the 492 patients selected for deferred therapy, predictive factors of improved overall survival were, not surprisingly, younger age and lack of comorbidities, but also male sex (Cohen et al , ).…”

“…A large study of 8,029 MCL patients showed that among the 492 patients selected for deferred therapy, predictive factors of improved overall survival were, not surprisingly, younger age and lack of comorbidities, but also male sex (Cohen et al , ). Another study of 162 relapsed/refractory MCL patients treated with ASCT ( n = 111) or allogeneic SCT ( n = 51) showed a higher SCT‐specific comorbidity index to be a significant risk factor for worse overall survival (Yamasaki et al , ). A recent investigation showed that allogeneic SCT in non‐Hodgkin lymphoma patients aged >65 years provided similar lymphoma control as in younger patients but was associated with higher non‐relapse mortality not fully explained by comorbidity (Kyriakou et al , ).…”

“…Male sex was recently shown as an independent predictor for worse survival in elderly DLBCL patients (Eyre et al, 2019). Assessment of the impact of comorbidity in MCL has so far almost exclusively been restricted to the group eligible for transplantation (Yamasaki et al, 2018;Kyriakou et al, 2019) and only one study has investigated the impact on all-cause survival in MCL of all ages (Cohen et al, 2016). In the era of targeted therapy, novel adverse events are expected (Arora & Portell, 2018;Ye et al, 2018), and having comorbidities may further increase the risk of side effects from the treatments, emphasizing the importance of benchmarking survival also in these groups.…”

Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis

“…After screening the full texts of the 55 remaining articles against the inclusion and exclusion criteria, an additional 37 articles were excluded for the following reasons: the study did not compare auto-SCT to allo-SCT (29 studies), did not enroll patients with relapsing/refractory NHL (3 studies), were not for B-NHL (2 studies), or did not report the outcome of interest (3 studies). As a result, 18 articles were finally eligible for inclusion in this meta-analysis [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] .…”

Risks of Muscle Atrophy in Patients with Malignant Lymphoma after Autologous Stem Cell Transplantation

“…Patients began treatment with upfront high-dose chemotherapy followed by ASCT after induction and consolidation chemotherapy. The pre-transplant conditioning regimen administered before ASCT was the LEED regimen, consisting of cyclophosphamide (60 mg/kg on days before ASCT 4 and 3), etoposide (250 mg/m 2 twice daily from days before ASCT 4 to 2), melphalan (130 mg/m 2 on the day before ASCT 1 ) , and dexamethasone ( 40 mg / body from days before ASCT 4 to 1) 20 ) and the MCEC regimen consisting of ranimustine (200 mg/m 2 on days before ASCT 8 and 3), carboplatin (300 mg/m 2 from days before ASCT 7 to 4), etoposide (500 mg/m 2 from days before ASCT 6 to 4), and cyclophosphamide (50 mg/kg on days before ASCT 3 and 2) [20][21][22] .…”